SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-66866"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-66866" > Effects of the oral...

  • Hillarp, AndreasLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,University and Reg Labs Reg Scania (författare)

Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

  • Artikel/kapitelEngelska2011

Förlag, utgivningsår, omfång ...

  • Blackwell Publishing,2011
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-66866
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-66866URI
  • https://doi.org/10.1111/j.1538-7836.2010.04098.xDOI
  • https://lup.lub.lu.se/record/1711172URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:122100988URI
  • https://gup.ub.gu.se/publication/162216URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • This is the authors’ version of the following article: A Hillarp, F Baghaei, I Fagerberg Blixter, K M Gustafsson, L Stigendal, M Sten-Linder, K Strandberg and Tomas Lindahl, Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays, 2011, JOURNAL OF THROMBOSIS AND HAEMOSTASIS, (9), 1, 133-139. which has been published in final form at: http://dx.doi.org/10.1111/j.1538-7836.2010.04098.x Copyright: Blackwell Publishing http://eu.wiley.com/WileyCDA/Brand/id-35.html
  • Introduction: Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary but the dose-dependent effects on common reagents and assay procedures are largely unknown. Objectives: To investigate the effect of rivaroxaban on commonly used coagulation assays. Materials and Methods: Rivaroxaban was added to plasma from healthy subjects in the concentration range 0-1000 mu g L-1 and analyzed using different reagents for activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin, fibrinogen and activated protein C (APC) resistance assays. Results: At an expected peak concentration of rivaroxaban in clinical use, the APTTs were almost invariably prolonged but at lower concentrations the effect was weak. The concentration needed to double the APTT varied between 389 +/- 106 and 617 +/- 149 mu g L-1 for different reagents. The PT assays showed a marked degree of difference. In general, the Quick PT type assays were more sensitive compared with the Owren type PT assays. The results from antithrombin assays were dependent on the type of reagent, with the Xa-based assay being sensitive for rivaroxaban with an estimated increase of 0.09 IU mL-1 per 100 mu g L-1 rivaroxaban. There were only minor effects on fibrinogen assays based on thrombin reagents. The APTT-based assay for APC resistance is affected in a dose-dependent manner whereas an assay based on the activation of coagulation at the prothrombinase level was unaffected. Conclusions: Different assays, and even different reagents within an assay group, display variable effects by therapeutic concentrations of rivaroxaban.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Baghaei, Fariba,1964Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine,Sahlgrens University Hospital(Swepub:gu)xbagfa (författare)
  • Fagerberg Blixter, Inger,1956Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för klinisk kemi och transfusionsmedicin,Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine,University of Gothenburg(Swepub:gu)xfagei (författare)
  • Gustafsson, K MLinköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet (författare)
  • Stigendal, LennartGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine,Sahlgrens University Hospital(Swepub:gu)xstile (författare)
  • Sten-Linder, MKarolinska Institutet,Karolinska Institute (författare)
  • Strandberg, KarinLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,University and Reg Labs Reg Scania(Swepub:lu)klke-kst (författare)
  • Lindahl, TomasÖstergötlands Läns Landsting,Linköpings universitet,Klinisk kemi,Hälsouniversitetet(Swepub:liu)tomli13 (författare)
  • Klinisk kemi, MalmöForskargrupper vid Lunds universitet (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:JOURNAL OF THROMBOSIS AND HAEMOSTASIS: Blackwell Publishing9:1, s. 133-1391538-79331538-7836

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy